GlassScriptPhysician profile
Max M Ghannadi
NPI 1114191798
$2,796.13
in general payments reported to CMS, 2019-2025
20 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $327 · 2021: $413 · 2022: $617 · 2023: $660 · 2024: $255 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.08 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $536.56 | 2022-2025 | Wegovy, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.22 | 2019-2025 | Jardiance |
| Amgen INC. | $334.16 | 2020-2023 | Repatha |
| Lilly USA, LLC | $321.66 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $263.66 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $217.65 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $139.63 | 2019-2023 | Breztri |
| Idorsia Pharmaceuticals US INC | $119.07 | 2024 | Quviviq |
| Pfizer INC. | $99.83 | 2019-2024 | |
| Gilead Sciences, INC. | $93.19 | 2023-2025 | |
| Abbvie INC. | $47.60 | 2023 | |
| Amarin Pharma, INC. | $42.14 | 2019 | |
| Ironwood Pharmaceuticals, INC | $42.14 | 2020 | |
| Scilex Pharmaceuticals INC. | $37.15 | 2022-2023 | Ztlido |
| Horizon Therapeutics Plc | $26.24 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.63 | 2020 | |
| Novartis Pharmaceuticals Corporation | $23.93 | 2021 | |
| Merck Sharp & Dohme LLC | $23.09 | 2021 | |
| Shield Therapeutics INC | $14.58 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Ghannadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.